Clifford Chance Moscow has advised 11 international banks on a USD 850 million pre-export financing for Uralkali, one of the world’s largest potash producers. CMS advised Uralkali on the financing.
DLA Piper has advised the FiveTen Group on its sale of Antal Russia, one of the largest recruitment companies in Russia and other CIS countries, back to the Antal International Group.
4th and 5th of October 2017 in Casablanca, Morocco
Kazan Legal 2017, taking place on 14 – 16th September, will deliver a fresh take on the latest developments in Russia and the CIS, but most importantly it will encourage dialogue between business, advisors and policy makers. The Forum’s social and cultural program will give you the opportunity to get to know the real Tatarstan, voted Russia’s most investor-friendly region, with its amazing heritage, cuisine and hospitality.
The development of modern technologies and the growing role of electronic documents in commercial relations influence the employment sphere, among others. Companies increasingly use electronic employment agreements and electronic policies, which increases the efficiency of employment paperwork turnaround. However, the positions of Russian employment law and the courts on electronic employment documentation are not uniform.
Intellectual Property protection in its modern sense is considered to be quite young in Russia. Although Russia is not far behind world standards for protection and enforcement of Intellectual Property, major changes took place in Russia in 2008. Almost ten years ago the Fourth Chapter of the Russian Civil Code incorporating various Intellectual Property-related rules came into effect. Of course, this area of law is still changing, leading to new amendments, improvement proposals, and legal discussions.
Clifford Chance's Moscow office has advised Pfizer on its agreement to provide finance and technology to Russian pharmaceutical company NovaMedica for the construction of a new production facility in Russia, with the medicines licensed and manufactured under the agreement to be sold by Pfizer and NovaMedica in Russia and the CIS.